Abstract
The fetus may be exposed to increased endogenous or synthetic glucocorticoid (GS) exposure in late gestation. Approximately 7% of pregnant women in Europe and North America are treated with synthetic GSs to promote lung maturation in fetuses at risk of preterm delivery. Maternal steroid treatment before preterm delivery is one of the best documented and most cost effective life saving treatments in prenatal medicine but, in certain circumstances, the price of accelerated lung maturity may be loss of brain cells, increased neurodevelopmental disability, intra-uterine growth restriction (IUGR), and an increased risk of preterm delivery, of programming of post-natal hypertension, and of increased postnatal activity in the hypothalamo-pituitary-adrenal (HPA) axis. Placental 11β-hydroxysteroid dehydrogenase type 2 (11β- HSD2) is the key enzyme which protects the fetus from overexposure to GSs by their oxidation into inactive derivates. We review the evidence for the metabolism of GSs during pregnancy and how endogenous and synthetic GSs cause other changes in the placenta which affect fetal development.
Keywords: Antenatal exposure, glucocorticoids, 11β-hydroxysteroid dehydrogenase, metabolism, placental transport, pregnancy, fetus, synthetic glucocorticoid, steroid treatment, increased neurodevelopmental disability, intra-uterine growth restriction (IUGR), hypothalamo-pituitary-adrenal, fetal development
Current Pharmaceutical Biotechnology
Title: Glucocorticoids in Pregnancy
Volume: 12 Issue: 5
Author(s): Beata Marciniak, Jolanta Patro-Malysza, Elzbieta Poniedzialek-Czajkowska, Zaneta Kimber-Trojnar, Bozena Leszczynska-Gorzelak and Jan Oleszczuk
Affiliation:
Keywords: Antenatal exposure, glucocorticoids, 11β-hydroxysteroid dehydrogenase, metabolism, placental transport, pregnancy, fetus, synthetic glucocorticoid, steroid treatment, increased neurodevelopmental disability, intra-uterine growth restriction (IUGR), hypothalamo-pituitary-adrenal, fetal development
Abstract: The fetus may be exposed to increased endogenous or synthetic glucocorticoid (GS) exposure in late gestation. Approximately 7% of pregnant women in Europe and North America are treated with synthetic GSs to promote lung maturation in fetuses at risk of preterm delivery. Maternal steroid treatment before preterm delivery is one of the best documented and most cost effective life saving treatments in prenatal medicine but, in certain circumstances, the price of accelerated lung maturity may be loss of brain cells, increased neurodevelopmental disability, intra-uterine growth restriction (IUGR), and an increased risk of preterm delivery, of programming of post-natal hypertension, and of increased postnatal activity in the hypothalamo-pituitary-adrenal (HPA) axis. Placental 11β-hydroxysteroid dehydrogenase type 2 (11β- HSD2) is the key enzyme which protects the fetus from overexposure to GSs by their oxidation into inactive derivates. We review the evidence for the metabolism of GSs during pregnancy and how endogenous and synthetic GSs cause other changes in the placenta which affect fetal development.
Export Options
About this article
Cite this article as:
Marciniak Beata, Patro-Malysza Jolanta, Poniedzialek-Czajkowska Elzbieta, Kimber-Trojnar Zaneta, Leszczynska-Gorzelak Bozena and Oleszczuk Jan, Glucocorticoids in Pregnancy, Current Pharmaceutical Biotechnology 2011; 12 (5) . https://dx.doi.org/10.2174/138920111795470868
DOI https://dx.doi.org/10.2174/138920111795470868 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) Transdermal Delivery of Diltiazem Hydrochloride from Poloxamer-HPMC Gel: in vitro, ex vivo, and in vivo Studies
Drug Delivery Letters Antioxidant Activity of Two Wild Edible Mushrooms (Morchella vulgaris and Morchella esculanta) from North Turkey
Combinatorial Chemistry & High Throughput Screening Neurovascular Role of Sympathetic Nervous System and Beta-Adrenoceptor Polymorphisms in Obesity and Hypertension
Current Hypertension Reviews Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Antithrombotic Options for Atrial Fibrillation in 2012
Cardiovascular & Hematological Disorders-Drug Targets Efficacy and Safety of Bevacizumab in Glioblastomas
Current Medicinal Chemistry Gas Bioengineering Using Hemoglobin-Vesicles For Versatile Clinical Applications
Current Pharmaceutical Design Neural Control of Blood Pressure: Focusing on Capsaicin-Sensitive Sensory Nerves
Cardiovascular & Hematological Disorders-Drug Targets Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology Editorial (Thematic Issue: Current Progress in the Development of Metalloprotein Inhibitors)
Current Topics in Medicinal Chemistry Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Prediabetic Dysglycemia: Call for Action
Current Diabetes Reviews Paris Saponin VII Induces Apoptosis and Cell Cycle Arrest in Erythroleukemia Cells by a Mitochondrial Membrane Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Transcription Factor CHF1/Hey2 Regulates Specific Pathways in Serum Stimulated Primary Cardiac Myocytes: Implications for Cardiac Hypertrophy
Current Genomics